Novel, highly effective and selective anticancer metallodrugs
Goal: The objective of this project is the synthesis of novel gold anticancer drugs that simultaneously target the mitochondrial proteins that are associated with cancer progression. Gold(III) complexes will be designed that recognize the translocator protein which is overexpressed in various tumour types and that release the metal upon intracellular reduction to gold(I), a known inhibitor of thioredoxin reductase. Binding of the carrier ligand to the translocator protein and inhibition of thioredoxin reductase will induce cell death pathways in a synergistic manner, thus leading to highly effective and selective anticancer action.
This project is funded by the European Commission (MSCA-Individual Scholarship).